Rare Biomarkers Specimen Collection and Stabilization Market
Rare Biomarkers Specimen Collection and Stabilization Market
Segments - Global Rare Biomarkers Specimen Collection and Stabilization Market By Products (Isolation Kits & Reagents, Blood Collection Tubes, and Systems), Types (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles), Specimens (Serum/Plasma and Others), Nucleic Acid & Other Biomolecules (RNA (Ribonucleic Acid), DNA (Deoxyribonucleic Acid), and Others), Applications (NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others), End-users (Research [Research Labs/CROs and Academic Institutes], Diagnostics [Laboratories, Hospitals, and Prenatal Clinics]), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa), Forecast 2022 – 2030
Upcoming
| Report ID :HC-3946
| 4.7 Rating
| 62 Reviews
| 165 Pages
| Format :
Report Description
The global rare biomarkers specimen collection and stabilization market size was USD 23.5 Bn in 2021 and is likely to reach USD 50.2 Bn by 2030, expanding at a CAGR of 8.8% during 2022-2030. The market growth is attributed to the increasing number of research study projects showing how circulating biomarkers are playing a role in controlling diseases and the rising demand for non-invasive disease diagnosis.
The number of research projects in the biomarkers area has expanded dramatically in recent years. The growing quantity of scientific papers on rare biomarker specimen collection and stabilization methods reflects healthcare organizations' interest in this market. Furthermore, growing evidence of uncommon biomarkers efficacy in illness management has prompted investments in clinical applications.
Researchers are embracing increasingly sensitive, quick, and flexible analytical technologies due to the promise of circulating biomarkers as high-value medication delivery systems and possible diagnostics. For enhancing research possibilities, the key players in the global market are creating novel technologies and solutions for collecting and stabilizing these uncommon biomarkers specimens. Companies implementing or developing liquid biopsy are recognized as one of the leading growth drivers in the market for collecting and stabilizing rare biomarker specimens in clinical settings.
COVID-19 Impact on Rare Biomarkers Specimen Collection and Stabilization Market
The market report finds that the COVID-19 pandemic has had a positive impact on global market growth. The pandemic and subsequent lockdowns affected several major industries. However, the market for the biomarkers industry witnessed significant growth, as it is vital in developing medicines for a chronic and rare types of diseases.
Several studies have revealed that biomarkers are important in diagnosing and treating COVID-19 infections. The research and development activities rose sharply in the past couple of years due to support and investment by government and private players, which helped the market to witness upward growth during the pandemic.
Rare Biomarkers Specimen Collection and Stabilization Market Dynamics
The research report presents a complete market overview by providing detailed information about the current market trends, existing drivers, growth opportunities and potentials, and emerging challenges. The global rare biomarkers specimen collection and stabilization market report has up-to-date insights about market scenarios that can shape the overall market performance and output during the forecast period, 2022 to 2030.
What are the Key Trends in Rare Biomarkers Specimen Collection and Stabilization Market?
Rising Demand for Non-invasive Cancer Diagnostics
The preference for non-invasive cancer diagnostics is rising, which is one of the primary trends in the global market. The growing number of cancer cases across the world is increasing the need for diagnostics methods that are non-invasive in nature.
The conventional cancer detection methods are highly concerning due to their less effectiveness in diagnosing small cancers, especially in detecting breast cancer in women who have dense breast tissues. These methods are complicated and time-consuming, which is why the need for simple and non-invasive techniques is growing in cancer detection. The introduction of liquid biopsy for cancer management has significantly impacted the market dynamics for uncommon biomarker specimen collection and stabilization tubes.
The new advances in liquid biopsy based on body fluids analysis are gaining wide attention for detecting cancer biomarkers. The introduction of liquid biopsy for cancer management has significantly impacted the market dynamics for uncommon biomarker specimen collection and stabilization tubes. The biomarkers analysis on blood, urine, sweat, tears, and other bodily fluids presents a significant opportunity for an early and non-invasive way of cancer detection.
What are the Drivers of Rare Biomarkers Specimen Collection and Stabilization Market?
Growing Demand for Accurate and Appropriate Diagnosis for Rare Diseases
Growing demand for accurate and appropriate diagnoses for rare diseases is projected to significantly drive the market for rare biomarkers specimen collection and stabilization in the coming years. The increasing population across the globe and increased prevalence of chronic diseases such as cardiovascular and diabetic patients are expected to contribute to increasing demand for biomarkers. Biomarkers collection and analysis enable accurate and appropriate analysis, owing to which its demand is expected to grow in the coming years, across the healthcare industry.
Rising Demand for Personalized and Precision Medicines
The increased demand for personalized medicine is another major driver fueling the rare biomarkers specimen collection and stabilization market growth. Biomarkers are important tools for the development of personalized and precision medicines.
Biomarkers enable medical researchers to define disease status and determine how the human body reacts to certain disease types or modulating agents. It also provides the opportunity to predict how a population with a specific type of disease benefits from personalized medicines.
What are the Major Restraints for Rare Biomarkers Specimen Collection and Stabilization Market?
High Investment, Treatment Costs, and Scarcity of Skilled Workers
The biomarkers equipment and technology require high investment from the healthcare establishment which is anticipated the hamper the market growth. Another major restraining factor is the treatment costs are high with the use of biomarkers and do not have the right reimbursements. Moreover, the scarcity of skilled healthcare workers in emerging economies possess a major challenge that can hinder market growth in the coming years.
What are the Opportunities in Rare Biomarkers Specimen Collection and Stabilization Market?
Increasing Research & Development Activities and Technological Advancements
Increasing initiatives for exosome research by various government and non-government organizations are expected to create growth opportunities for key players. In addition, technological advancements in biomarker isolation are estimated to create opportunities for market players. The improved diagnostics and development of personalized treatments and medicines with the help of advanced technology is expected to create lucrative growth opportunity for the global market.
Scope of Rare Biomarkers Specimen Collection and Stabilization Market Report
The report on the global rare biomarkers specimen collection and stabilization market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Rare Biomarkers Specimen Collection and Stabilization Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2021 |
|
Historic Data |
2019–2020 |
|
Forecast Period |
2022–2030 |
|
Segmentation |
Products (Isolation Kits & Reagents, Blood Collection Tubes, and Systems), Types (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and Exosomes/Extracellular Vesicles), Specimens (Serum/Plasma and Others), Nucleic Acid & Other Biomolecules (RNA (Ribonucleic Acid), DNA (Deoxyribonucleic Acid), and Others), Applications (NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, and Others), and End-users (Research [Research Labs/CROs and Academic Institutes], Diagnostics [Laboratories, Hospitals, and Prenatal Clinics]) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Advanced Cell Diagnostics, Inc., Agena Bioscience, ANGLE plc, ApoCell, Inc., AS One InternationalNTERNATIONAL, BioChain Institute, Inc., Biolidics Limited, Biomatrica, Bio-Techne Corporation, BioVision, Inc., Caltag Medsystems Limited, Cytomark Ltd., DNA Genotek, Inc., Epic Sciences, EpiGentek Group Inc., F. Hoffmann-La Roche Ltd, Fluxion Biosciences, Inc., Geno Technology Inc., Genomax Technologies Pte Ltd., and GILUPI GmbH. |
Rare Biomarkers Specimen Collection and Stabilization Market Segment Insights
Which Major Factors Influence the Significant Growth of the Blood Collection Tubes Segment?
Increasing Need for Sample Collection For Diagnosing Rare and Genetic Diseases
Based on the products, the market can be divided into isolation kits & reagents, blood collection tubes, and systems. The blood collection tube segment is anticipated to hold a significant market share during the forecast period. The increasing aged population and prevalence of chronic diseases and cancer across the globe are driving the demand for blood collection tubes in the market. The blood collection tubes are used for sample collection for diagnosing rare and genetic diseases.
Isolation kits & reagents segment is projected to grow at a rapid pace in the coming years. The increasing prevalence of rare and chronic diseases is likely to boost the requirement for isolation kits and reagents in the global market. The growing investment in exploring the use of biomarkers for prognosis, diagnosis, and treatment of rare disorders is boosting the segment in the global market.
What are the Major Reasons for High Revenue Generation in Circulating Cell Free DNA (ccfDNA)?
Growing Adoption of Non-Invasive Prenatal Testing (NIPT)
In terms of types, the rare biomarkers specimen collection and stabilization market is segregated into circulating cell free DNA (ccfDNA), circulating tumor cells (CTCs), and exosomes/extracellular vesicles. Circulating cell free DNA (ccfDNA) segment held the major share of the market in 2021 and is projected to grow at a rapid pace during the forecast period.
The segment growth is attributed to the rising adoption of NIPT in testing chromosomal anomalies in the fetus. The test is efficient in detecting cancer. Circulating tumor cells (CTCs) are a rare group of cells identified in the blood of solid tumor patients that serve as a seed for metastasis. The increasing incidence of different types of cancer is driving the CTCs segment growth.
What are the Main Aspects for Boosting the Serum/plasma Segment?
Increasing Diagnostic Tests Using Body Fluids
On the basis of specimens, the rare biomarkers specimen collection and stabilization market can be classified as serum/plasma and others. Serum/plasma segment is expected to expand at a substantial pace during the forecast period owing to rising diagnostic tests using body fluids.
Serum and plasma are both derived from the liquid portion of the blood that remains after the cells have been removed. The liquid that remains after the blood has clots is known as serum. When clotting is stopped with the use of an anticoagulant, the liquid that remains is called plasma.
What Key Factors Contribute to the Rapid Expansion of the DNA Segment?
Growing Demand for Personalized Treatments and Medicine
In terms of nucleic acid & other biomolecules, the market can be segmented into RNA, DNA, and others. DNA segment is anticipated to exhibit a robust pace of growth during the forecast period. Deoxyribonucleic Acid (DNA) is information containing molecule. It consists of information in regards to developing other large-size molecules called proteins.
Ribonucleic Acid (RNA) is a polymeric molecule that plays a variety of roles in biology, including gene coding, decoding, regulation, and expression. Deoxyribonucleic acid is a molecule composed of polynucleotide chains that coil round every different to shape a double helix wearing genetic commands for the development, growth, functioning, and reproduction of all recognized organisms and many viruses.
What are the Major Reasons for High Revenue Generation in Oncology?
Rising Focus of Government and Private Organizations to Curb Cancer
Based on applications, the rare biomarkers specimen collection and stabilization market can be segregated into NIPT, oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and others. The oncology segment is expected to hold a substantial market share during the forecast period due to the rise in various government and non-government initiatives to curb the occurrence of cancer diseases.
What are the Main Aspects for Boosting the Research Segment?
Rising Research & Development Activities in Healthcare and Pharmaceutical Sector
Based on end-users, the global market is bifurcated into research and diagnostics. The research is further divided into Labs/CROs and Academic Institutes. The diagnostics segment is further categorized into Laboratories, Hospitals, and Prenatal Clinics. The research segment is expected to expand at a significant growth rate during the projected period owing to rising research and development activities across the worldwide healthcare industry.
The diagnostics segment is projected to hold a key market share in the coming years. The biomarkers are beneficial in the effective diagnosis of chronic and rare types of diseases. The growing demand for effective diagnosis and rising diagnostics centers is expected to support the segment’s growth in the coming years.
Why is North America Dominating the Global Rare Biomarkers Specimen Collection and Stabilization Market?
Presence of a Large Client-base and a Large Number of FDA-Authorized Products
On the basis of regions, the market can be categorized as Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. North America is anticipated to account for a large market share revenue. The presence of a large client base, as well as a large number of FDA-authorized products, are key factors driving the region's strong growth in the market.
Furthermore, with the growing requirement for liquid biopsy and assisted reproductive technologies in the region, the number of approved isolation kits for clinical and research usage is expected to rise in the region.
Asia Pacific is expected to witness rapid growth in the global market during the projection period. The ongoing research and developments in biomarkers are projected to support the market growth in the region. The rising health awareness and government support from developing countries of the region are also projected to fuel the market expansion during the forecast period.
Segments
The global rare biomarkers specimen collection and stabilization market has been segmented on the basis of
Products
-
Isolation Kits & Reagents
-
Blood Collection Tubes
-
Systems
Types
-
Circulating Call Free DNA (ccfDNA)
-
Circulating Tumor Cells (CTCs)
-
Exosomes/Extracellular Vesicles
Specimens
-
Serum/Plasma
-
Others
Nucleic Acid & Other Biomolecules
-
RNA (Ribonucleic Acid)
-
DNA (Deoxyribonucleic Acid)
-
Others
Applications
-
NIPT
-
Oncology
-
Transcriptomics
-
Pharmacogenomics
-
Transplant Rejection
-
Population Screening
-
Cardiovascular
-
Diseases
-
Others
End-users
-
Research
-
Research Labs/CROs
-
Academic Institutes
-
-
Diagnostics
-
Laboratories
-
Hospitals
-
Prenatal Clinics
-
Regions
-
Asia Pacific
-
North America
-
Europe
-
Latin America
-
Middle East & Africa
Key Players
-
Agena Bioscience
-
ApoCell, Inc.
-
AS One International
-
BioChain Institute, Inc.
-
Biolidics Limited
-
Biomatrica
-
Bio-Techne Corporation
-
BioVision, Inc.
-
Caltag Medsystems Limited,
-
Cytomark Ltd.
-
DNA Genotek, Inc.
-
Epic Sciences
-
EpiGentek Group Inc.
-
F. Hoffmann-La Roche Ltd
-
Fluxion Biosciences, Inc.
-
Geno Technology Inc.
-
Genomax Technologies Pte Ltd.
-
GILUPI GmbH
Competitive Landscape
The competitive landscape of the global rare biomarkers specimen collection and stabilization market report provides key insights into the growth strategies and development initiatives implemented by the key players in the market.
Some of the key players in the rare biomarkers specimen collection and stabilization market include Advanced Cell Diagnostics, Inc., Agena Bioscience, ANGLE plc, ApoCell, Inc., AS One lNTERNATIONAL, BioChain Institute, Inc., Biolidics Limited, Biomatrica, Bio-Techne Corporation, BioVision, Inc., Caltag Medsystems Limited, Cytomark Ltd., DNA Genotek, Inc., Epic Sciences, EpiGentek Group Inc., F. Hoffmann-La Roche Ltd, Fluxion Biosciences, Inc., Geno Technology Inc., Genomax Technologies Pte Ltd., and GILUPI GmbH.
Some of these major companies adopted various business development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production capacity expansion to expand their consumer base and enhance their market share.
Frequently Asked Questions
The global rare biomarkers specimen collection and stabilization market size was USD 23.5 Bn in 2021 and is likely to reach USD 50.2 Bn by 2030.
Increasing research activities to depict the role of circulating biomarkers in disease management, as well as rising demand for non-invasive cancer diagnostic and personalized medicines, are the primary drivers of the global rare biomarkers specimen collection and stabilization market.
The global rare biomarkers specimen collection and stabilization market is estimated to register a compound annual growth rate of around 8.8% during the forecast period.
For regional analysis, North America dominates the global market.
Some of the key global rare biomarkers specimen collection and stabilization market players are Advanced Cell Diagnostics, Inc., Agena Bioscience, ANGLE plc, ApoCell, Inc., AS One InternationalNTERNATIONAL, BioChain Institute, Inc., Biolidics Limited, Biomatrica, Bio-Techne Corporation, BioVision, Inc., and Caltag Medsystems Limited.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Rare Biomarkers Specimen Collection and Stabilization Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Rare Biomarkers Specimen Collection and Stabilization Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Rare Biomarkers Specimen Collection and Stabilization Market - Supply Chain
4.5. Global Rare Biomarkers Specimen Collection and Stabilization Market Forecast
4.5.1. Rare Biomarkers Specimen Collection and Stabilization Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Rare Biomarkers Specimen Collection and Stabilization Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Rare Biomarkers Specimen Collection and Stabilization Market Absolute $ Opportunity
5. Global Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
5.3.1. Circulating Call Free DNA (ccfDNA)
5.3.2. Circulating Tumor Cells (CTCs)
5.3.3. Exosomes/Extracellular Vesicles
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
6.3.1. NIPT
6.3.2. Oncology
6.3.3. Transcriptomics
6.3.4. Pharmacogenomics
6.3.5. Transplant Rejection
6.3.6. Population Screening
6.3.7. Cardiovascular
6.3.8. Diseases
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast by End Users
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by End Users
7.2.2. Y-o-Y Growth Projections by End Users
7.3. Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by End Users
7.3.1. Research Research Labs/CROs Academic Institutes Diagnostics Laboratories Hospitals Prenatal Clinics
7.4. Absolute $ Opportunity Assessment by End Users
7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
9. North America Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
9.4.1. Circulating Call Free DNA (ccfDNA)
9.4.2. Circulating Tumor Cells (CTCs)
9.4.3. Exosomes/Extracellular Vesicles
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. North America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
9.7.1. NIPT
9.7.2. Oncology
9.7.3. Transcriptomics
9.7.4. Pharmacogenomics
9.7.5. Transplant Rejection
9.7.6. Population Screening
9.7.7. Cardiovascular
9.7.8. Diseases
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. North America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by End Users
9.10.1. Research Research Labs/CROs Academic Institutes Diagnostics Laboratories Hospitals Prenatal Clinics
9.11. Basis Point Share (BPS) Analysis by End Users
9.12. Y-o-Y Growth Projections by End Users
9.13. Market Attractiveness/Growth Potential Analysis
9.13.1. By Country
9.13.2. By Product Type
9.13.3. By Application
9.14. North America Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
10. Latin America Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
10.4.1. Circulating Call Free DNA (ccfDNA)
10.4.2. Circulating Tumor Cells (CTCs)
10.4.3. Exosomes/Extracellular Vesicles
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Latin America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
10.7.1. NIPT
10.7.2. Oncology
10.7.3. Transcriptomics
10.7.4. Pharmacogenomics
10.7.5. Transplant Rejection
10.7.6. Population Screening
10.7.7. Cardiovascular
10.7.8. Diseases
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Latin America Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by End Users
10.10.1. Research Research Labs/CROs Academic Institutes Diagnostics Laboratories Hospitals Prenatal Clinics
10.11. Basis Point Share (BPS) Analysis by End Users
10.12. Y-o-Y Growth Projections by End Users
10.13. Market Attractiveness/Growth Potential Analysis
10.13.1. By Country
10.13.2. By Product Type
10.13.3. By Application
10.14. Latin America Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
11. Europe Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
11.4.1. Circulating Call Free DNA (ccfDNA)
11.4.2. Circulating Tumor Cells (CTCs)
11.4.3. Exosomes/Extracellular Vesicles
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Europe Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
11.7.1. NIPT
11.7.2. Oncology
11.7.3. Transcriptomics
11.7.4. Pharmacogenomics
11.7.5. Transplant Rejection
11.7.6. Population Screening
11.7.7. Cardiovascular
11.7.8. Diseases
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Europe Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by End Users
11.10.1. Research Research Labs/CROs Academic Institutes Diagnostics Laboratories Hospitals Prenatal Clinics
11.11. Basis Point Share (BPS) Analysis by End Users
11.12. Y-o-Y Growth Projections by End Users
11.13. Market Attractiveness/Growth Potential Analysis
11.13.1. By Country
11.13.2. By Product Type
11.13.3. By Application
11.14. Europe Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
12. Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
12.4.1. Circulating Call Free DNA (ccfDNA)
12.4.2. Circulating Tumor Cells (CTCs)
12.4.3. Exosomes/Extracellular Vesicles
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
12.7.1. NIPT
12.7.2. Oncology
12.7.3. Transcriptomics
12.7.4. Pharmacogenomics
12.7.5. Transplant Rejection
12.7.6. Population Screening
12.7.7. Cardiovascular
12.7.8. Diseases
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by End Users
12.10.1. Research Research Labs/CROs Academic Institutes Diagnostics Laboratories Hospitals Prenatal Clinics
12.11. Basis Point Share (BPS) Analysis by End Users
12.12. Y-o-Y Growth Projections by End Users
12.13. Market Attractiveness/Growth Potential Analysis
12.13.1. By Country
12.13.2. By Product Type
12.13.3. By Application
12.14. Asia Pacific Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
13. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Middle East & Africa Average Pricing Analysis
13.2. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Types
13.4.1. Circulating Call Free DNA (ccfDNA)
13.4.2. Circulating Tumor Cells (CTCs)
13.4.3. Exosomes/Extracellular Vesicles
13.5. Basis Point Share (BPS) Analysis by Types
13.6. Y-o-Y Growth Projections by Types
13.7. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by Applications
13.7.1. NIPT
13.7.2. Oncology
13.7.3. Transcriptomics
13.7.4. Pharmacogenomics
13.7.5. Transplant Rejection
13.7.6. Population Screening
13.7.7. Cardiovascular
13.7.8. Diseases
13.8. Basis Point Share (BPS) Analysis by Applications
13.9. Y-o-Y Growth Projections by Applications
13.10. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Market Size and Volume Forecast by End Users
13.10.1. Research Research Labs/CROs Academic Institutes Diagnostics Laboratories Hospitals Prenatal Clinics
13.11. Basis Point Share (BPS) Analysis by End Users
13.12. Y-o-Y Growth Projections by End Users
13.13. Market Attractiveness/Growth Potential Analysis
13.13.1. By Country
13.13.2. By Product Type
13.13.3. By Application
13.14. Middle East & Africa Rare Biomarkers Specimen Collection and Stabilization Demand Share Forecast, 2019-2026
14. Competition Landscape
14.1. Global Rare Biomarkers Specimen Collection and Stabilization Market: Market Share Analysis
14.2. Rare Biomarkers Specimen Collection and Stabilization Distributors and Customers
14.3. Rare Biomarkers Specimen Collection and Stabilization Market: Competitive Dashboard
14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
14.4.1. Advanced Cell Diagnostics, Inc.
14.4.2. Agena Bioscience
14.4.3. ANGLE plc
14.4.4. ApoCell, Inc.
14.4.5. AS One International
14.4.6. BioChain Institute, Inc.
14.4.7. Biolidics Limited
14.4.8. Biomatrica
14.4.9. Bio-Techne Corporation
14.4.10. BioVision, Inc.
14.4.11. Caltag Medsystems Limited,
14.4.12. Cytomark Ltd.
14.4.13. DNA Genotek, Inc.
14.4.14. Epic Sciences
14.4.15. EpiGentek Group Inc.
14.4.16. F. Hoffmann-La Roche Ltd
14.4.17. Fluxion Biosciences, Inc.
14.4.18. Geno Technology Inc.
14.4.19. Genomax Technologies Pte Ltd.
14.4.20. GILUPI GmbH
Methodology
Related Reports
Some other reports from this category!
Our Clients
